Xbrane Biopharma (Sweden) and Helvetic BioPharma (Switzerland) have signed a sales and distribution agreement to debut Xbrane's biosimilar medicine, Xlucane (Ranibizuma), in Iran. Xlucane is a biosimilar version of Lucentis for the treatment of age-related muscular degeneration. Xbrane estimates the market size for wet AMD in Iran comprises approximately 70,000 patients and constitutes a leading cause of blindness in the country.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.243 SEK | +1.67% |
|
+3.85% | -97.57% |
05-22 | Xbrane Successfully Scale Up Xdivane- Biosimilar Candidate to Opdivo®? | CI |
05-16 | Transcript : Xbrane Biopharma AB, Q1 2024 Earnings Call, May 16, 2024 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-97.57% | 34.42M | |
+25.83% | 47.96B | |
+0.69% | 42.45B | |
+44.53% | 41.47B | |
+30.52% | 31.6B | |
+22.30% | 28.63B | |
-6.35% | 28.03B | |
+49.25% | 14.56B | |
+49.18% | 14.14B | |
+3.45% | 12.58B |
- Stock Market
- Equities
- XBRANE Stock
- News Xbrane Biopharma AB
- Xbrane Biopharma and Helvetic Biopharma (Switzerland) Sign a Sales and Distribution Agreement